A phase III, randomized, open-label study to compare pharmacokinetics, efficacy and safety of subcutaneous (SC) trastuzumab with intravenous (IV) trastuzumab administered in women with HER2 positive early breast cancer (EBC).

Trial Profile

A phase III, randomized, open-label study to compare pharmacokinetics, efficacy and safety of subcutaneous (SC) trastuzumab with intravenous (IV) trastuzumab administered in women with HER2 positive early breast cancer (EBC).

Completed
Phase of Trial: Phase III

Latest Information Update: 14 Sep 2017

At a glance

  • Drugs Trastuzumab (Primary) ; Trastuzumab (Primary) ; Cyclophosphamide; Docetaxel; Epirubicin; Fluorouracil
  • Indications Early breast cancer
  • Focus Pharmacokinetics; Registrational; Therapeutic Use
  • Acronyms HannaH
  • Sponsors Roche
  • Most Recent Events

    • 04 Feb 2017 Status changed from active, no longer recruiting to completed.
    • 19 May 2016 Results published in the European Journal of Cancer
    • 29 May 2015 Complete pathologic complete response and event-free survival results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top